Bioactivity-guided fractionation of the triglyceride-lowering component and in vivo and in vitro evaluation of hypolipidemic effects of Calyx seu Fructus Physalis
Open Access
- 1 January 2012
- journal article
- research article
- Published by Springer Science and Business Media LLC in Lipids in Health and Disease
- Vol. 11 (1), 38
- https://doi.org/10.1186/1476-511x-11-38
Abstract
In folklore, some people take the decoction of Calyx seu Fructus Physalis (CSFP) for lowering blood lipids. The present study is designed to evaluate the lipid-lowering activities of CSFP, and search for its pharmacodynamical material. CSFP was extracted by water and 75% ethanol, respectively. The extracts of CSFP for reducing serum lipid levels were evaluated on mouse model of hyperlipidemia. The optimized extract was subjected to the bioactivity-guided fractionation in which the liquid-liquid extraction, collumn chromatography, the in vivo and in vitro models of hyperlipidemia were utilized. The structure of active component was determined by 13 C-NMR and 1H-NMR. The 75% ethanol extract of CSFP decreased the serum total cholesterol (TC) and triglyceride (TG) levels in mouse model of hyperlipidemia. Followed a separation process for the 75% ethanol extract of CSFP, the fraction B was proved to be an active fraction for lowering lipid in vivo and in vitro experiments, which could significantly decrease the serum TC and TG levels in mouse model of hyperlipidemia, and remarkably decrease the increase of TG in primary mouse hepatocytes induced by high glucose and the increase of TG in HepG2 cells induced by oleic acid. The fraction B2, isolated from B on bioactivity-guided fractionation, could significantly decrease TG level in HepG2 cells. One compound with the highest content in B2 was isolated and determined as luteolin-7-O-beta-D-glucopyranoside by NMR spectra. It could significantly reduce the TG level in HepG2 cells, and inhibited the accumulation of lipids by oil red O stain. Our results demonstrated that the 75% ethanol extract of CSFP could improve in vitro and in vivo lipid accumulation. Luteolin-7-O-beta-D-glucopyranoside might be a leading pharmacodynamical material of CSFP for lowering lipids.Keywords
This publication has 16 references indexed in Scilit:
- Inhibitory effect of Physalis alkekengi L. var. franchetii extract and its chloroform fraction on LPS or LPS/IFN-γ-stimulated inflammatory response in peritoneal macrophagesJournal of Ethnopharmacology, 2011
- Citrus flavonoids repress the mRNA for stearoyl-CoA desaturase, a key enzyme in lipid synthesis and obesity control, in rat primary hepatocytesLipids in Health and Disease, 2011
- Reduction of lipid accumulation in HepG2 Cells by luteolin is associated with activation of AMPK and Mitigation of oxidative stressPhytotherapy Research, 2010
- Mechanisms Regulating Repression of Haptoglobin Production by Peroxisome Proliferator-Activated Receptor-γ Ligands in AdipocytesEndocrinology, 2010
- Antimicrobial activity of the extracts and physalin D fromPhysalis alkekengiand evaluation of antioxidant potential of physalin DPharmaceutical Biology, 2009
- Acetic Acid Upregulates the Expression of Genes for Fatty Acid Oxidation Enzymes in Liver To Suppress Body Fat AccumulationJournal of Agricultural and Food Chemistry, 2009
- A randomized, multicentre, open‐label, parallel‐group trial to compare the efficacy and safety profile of daming capsule in patients with hypercholesterolemiaPhytotherapy Research, 2009
- Use of a Low-Density Microarray for Studying Gene Expression Patterns Induced by Hepatotoxicants on Primary Cultures of Rat HepatocytesToxicological Sciences, 2003
- Inhibitory Activity of Minor Polyphenolic and Nonpolyphenolic Constituents of Olive Oil AgainstIn VitroLow-Density Lipoprotein OxidationJournal of Medicinal Food, 2002
- Flavonol Glycosides fromDavilla flexuosaJournal of the Brazilian Chemical Society, 1996